Confronting the “silent killer”: Advances in HCV testing and treatment
Dr. John Ward, MD
Director, Division of Viral Hepatitis
Atlanta, GA, USA | Mar 01, 2017
HCV infection is a significant contributor to chronic liver disease (CLD) worldwide. In the US, HCV is the leading cause of liver transplants. To address this growing threat, the CDC has recently issued a significant change to HCV screening guidelines to better identify undiagnosed cases that can lead to advanced disease and missed opportunities for treatment.
At the end of the presentation, attendees will be able to:
- Describe HCV natural history and epidemiology.
- Describe the key laboratory assays involved in an HCV diagnosis.
- Understand the value in the “birth cohort” screening recommendation.
- Discuss new treatment modalities that are expected to dramatically improve treatment efficacy.